Base on the recent study using a bivalent anti-HER2 engineered antibody25, the moderate affinity (KD) of FLAPs created in this study is within a clinically relevant range, suggesting that mono and multivalent anti-HER2 FLAPs are promising options for developing specific drugs against HER2-amplified cancers. Here, ERBB2 is linked to cancer.